Page 3 - ப்ரோக்ர்யாம் திசைமாற்றி குழு உறுப்பினர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study .
Myovant Sciences, Inc.January 26, 2021 GMT
84.8% and 73.3% of women reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain at one year
82.8% average reduction from baseline
on the Numerical Rating Scale for dysmenorrhea from 7.4 (severe pain) to 1.3 (mild pain)
over one year
Bone mineral density loss was minimal at Week 24 and remained stable through one year
Data to be included in New Drug Application submission to U.S. Food and Drug Administration anticipated in first half of 2021 ....

United States , San Francisco , Albert Liao , Bryan Crowe , Steve Danehy , James Rusnak , Chuck Triano , Linda Giudice , Juan Camilo Arjona Ferreira , University Of California , Program Steering Committee Member , Reproductive Sciences , Global Product Development At Pfizer , Pfizer Inc , Virtual Congress , Myovant Sciences Forward , American Society For Reproductive Medicine , Drug Administration , Myovant Sciences , Exchange Commission , Myovant Sciences Contacts , Myovant Sciences Inc , Sumitomo Dainippon Pharma Co Ltd , Sumitovant Biopharma Ltd , Program In Endometriosis , Numerical Rating Scale ,